Cilo Cybin expects significant loss increase in 2025 results

Cilo Cybin Holdings Limited (JSE: CCC) has issued a trading statement advising shareholders of an expected significant downturn in financial performance for the year ending March 31, 2025. The company anticipates reporting a basic loss per share between 0.8 cents and 0.9 cents, compared to basic earnings per share of 0.51 cents for the previous year, representing a decrease in excess of 100%. Similarly, headline loss per share is also projected to be between 0.8 cents and 0.9 cents, against headline earnings per share of 0.51 cents, also indicating a decrease exceeding 100%. Cilo Cybin reminds shareholders of its Share Purchase Agreement with Cilo Cybin Pharmaceutical, under which it will acquire 100% of the issued shares for a consideration of ZAR845 million, to be settled through the issue of Cilo Cybin shares. The anticipated loss is attributed to substantial one-off acquisition-related costs, including fees for assessments, advisory services, accounting and tax advice. The company's annual results will be released on SENS on or about June 27, 2025.